Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Read the full article at UK Investor Magazine

N4 Pharma (LON:N4P) is a consumer-driven pharmaceutical company developing reformulations of a number of key drugs. These have the potential to produce very attractive returns for shareholders in the form of an estimated £300 million of sales if they achieve full commerciality.

UK Investor Magazine – N4 Pharma: a consumer-driven reformulation and generics specialist